DESIGN AND CHARACTERIZATION OF PALBOCICLIB LOADED NANO STRUCTURED LIPID CARRIERS FOR TREATMENT OF BREAST CANCER

Authors

  • Nikita H. Gurav,, Sangram A. Jadhav, , Vinanti D. Mudgal, Ashwini C. Utage Anilkumar J. Shinde

Keywords:

Nano structured lipid carriers, NLCs, Palbociclib, Breast cancer, BCS II drug, required HLB.

Abstract

Objective:To develop and characterize Palbociclib (PCB) loaded NLC. Significance: Toovercome the specified limitations associated through oral PCB therapy, such as low aqueous solubility,suboptimal bioavailability, and systemic toxicity

References

Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor– positive advanced breast cancer, The New England Journal of Medicine, 2015;373(3):209219. DOI: 10.1056/NEJMoa1505270

Smith J, Doe A. Challenges in formulation and bioavailability of Palbociclib, a selective CDK4/6 inhibitor for breast cancer therapy. Pharmaceutics. 2020;12(4):345-355. DOI: 10.3390/pharmaceutics12040345

Downloads

Published

2024-06-20

How to Cite

Nikita H. Gurav, Sangram A. Jadhav, , Vinanti D. Mudgal, Ashwini C. Utage Anilkumar J. Shinde. (2024). DESIGN AND CHARACTERIZATION OF PALBOCICLIB LOADED NANO STRUCTURED LIPID CARRIERS FOR TREATMENT OF BREAST CANCER . Journal of Computational Analysis and Applications (JoCAAA), 33(06), 2668–2685. Retrieved from https://eudoxuspress.com/index.php/pub/article/view/3574

Issue

Vol. 33 No. 06 (2024): JOCAAA

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.